We’re accepting new patients! Let’s get started.

Discover SPRAVATO®

It’s the first FDA-approved nasal spray specifically for adults with treatment-resistant depression.

Ask your healthcare provider if SPRAVATO® may be right for you.

"Allison’s son tried many oral antidepressants without relief. Now, because of SPRAVATO®, Allison’s son is starting to feel like himself again. "
Allison
Mother of real patient with treatment-resistent depression
Discover SPRAVATO

If you struggle with treatment-resistant depression, there's a different choice to turn to.

If you’ve tried two or more antidepressants of adequate dose and duration and are still struggling with depressive symptoms, talk to your healthcare provider to see if you may have treatment-resistant depression. SPRAVATO® works differently than other medications for treatment-resistant depression. Today’s most commonly used oral antidepressants are thought to treat depression by increasing levels of neurotransmitters (serotonin, norepinephrine and dopamine) in areas of the brain that affect mood. SPRAVATO® targets the N-methyl-D-aspartate (NMDA) receptor and is believed to work differently than currently available oral antidepressants. The exact way that SPRAVATO® works is unknown. SPRAVATO® is taken with an oral antidepressant.

SPRAVATO® was proven effective for adults with treatment-resistant depression when taken with an oral antidepressant.

In a short-term clinical study of adults with treatment-resistant depression,* those who took SPRAVATO® and an oral antidepressant experienced a greater reduction of depression symptoms at four weeks (compared to those who received a placebo and an oral antidepressant).

In a long-term study after 16 weeks of therapy, patients who stayed on SPRAVATO®‡ were less likely to experience a return of depressive symptoms than those who stopped therapy.

*Adults with major depressive disorder who have not responded sufficiently to at least two different antidepressants of adequate dose and duration in the current episode. Based on an overall score on a standardized rating scale. ‡ Along with an oral antidepressant.

SPRAVATO® is also FDA-approved for Major Depressive Disorder with Suicidal Ideation.

In studies of patients with major depressive disorder and active suicidal thoughts or actions, those who took and an oral antidepressant experienced a greater reduction of depressive symptoms at 24 hours compared to those who received a placebo plus an oral antidepressant.* Further reductions were seen consistently through four weeks (25 days) of treatment, so it is important to follow the treatment plan that you and your healthcare provider have made. Not all patients will respond to SPRAVATO®.

It is not known if SPRAVATO® is safe and effective for use in preventing suicide or in reducing suicidal thoughts or actions. SPRAVATO® is not for use in place of hospitalization if your healthcare provider determines that hospitalization is needed, even if improvement is experienced after the first dose of SPRAVATO®.

Ask your healthcare provider if SPRAVATO® may be right for you. SPRAVATO® is not for use as a medicine to prevent or relieve pain (anesthetic). It is not known if SPRAVATO® is safe or effective as an anesthetic medicine. It is not known if SPRAVATO® is safe and effective in children.

Please see Important Safety Information in this brochure. Please see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider.

SPRAVATO® Side Effects

Serious side effects of SPRAVATO® include feeling sleepy (sedation); feeling disconnected from yourself, your thoughts, feelings and things around you (dissociation); abuse and misuse; increased risk of suicidal thoughts and behavior; increased blood pressure; problems with thinking clearly; and bladder problems. For additional information on these serious side effects, please see Important Safety Information in this brochure. These are not all the possible side effects of SPRAVATO®.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. Please see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider. cp-79822v3 © Janssen Pharmaceuticals, Inc.

SPRAVATO® may cause serious side effects including:

In studies of patients with major depressive disorder and active suicidal thoughts or actions, those who took and an oral antidepressant experienced a greater reduction of depressive symptoms at 24 hours compared to those who received a placebo plus an oral antidepressant.* Further reductions were seen consistently through four weeks (25 days) of treatment, so it is important to follow the treatment plan that you and your healthcare provider have made. Not all patients will respond to SPRAVATO®.

It is not known if SPRAVATO® is safe and effective for use in preventing suicide or in reducing suicidal thoughts or actions. SPRAVATO® is not for use in place of hospitalization if your healthcare provider determines that hospitalization is needed, even if improvement is experienced after the first dose of SPRAVATO®.

Ask your healthcare provider if SPRAVATO® may be right for you. SPRAVATO® is not for use as a medicine to prevent or relieve pain (anesthetic). It is not known if SPRAVATO® is safe or effective as an anesthetic medicine. It is not known if SPRAVATO® is safe and effective in children.

The most common side effects of SPRAVATO® when used along with an antidepressant taken by mouth include:

What to Expect

Visit SPRAVATO.com SPRAVATO® (esketamine) CIII nasal spray can only be administered under the supervision of a healthcare provider at a treatment center that is certified in the SPRAVATO® Risk Evaluation and Mitigation Strategy (REMS) Program. As part of the REMS, a healthcare provider will discuss the risks of sedation, dissociation, and abuse and misuse with you before starting SPRAVATO®. You and a healthcare provider must complete a Patient Enrollment Form for you to receive SPRAVATO® in a certified treatment center.

Discuss with Your Healthcare Provider Before Taking SPRAVATO®

SPRAVATO® is not for everyone. Talk to your healthcare provider about your full medical history, including if you:

Your First Treatment Center Visit

Your healthcare provider will continue to be involved with your care during SPRAVATO® treatment and will be available to answer questions or address concerns as you undergo treatment.

Your first visit to the certified SPRAVATO® treatment center will be a consultation. The treatment center will:

  • Receive your medical information from your healthcare provider
  • Conduct its own assessment to determine if SPRAVATO® may be right for you
  • Verify your insurance information as part of the eligibility confirmation

If SPRAVATO® is recommended, the treatment center will build a treatment plan with you and enroll you in the SPRAVATO® REMS Program.

SPRAVATO withMe– the support program that’s by your side from the start

SPRAVATO® is covered by most insurance and there are ways to help pay for it.

Do you struggle with treatment-resistant depression?

There's a different choice to turn to

Contact Catalyst Psychiatry to see if SPRAVATO® is right for you.